Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes Uncontrolled with Metformin Alone or with Sulfonylurea: The PIONEER 3 Randomized Clinical Trial

JAMA - Journal of the American Medical Association

Volumn 321, Issue 15, 2019, Pages 1466-1480

  Rosenstock, Julio ^a   Allison, Dale ^b   Birkenfeld, Andreas L ^c,d   Blicher, Thalia Marie ^e   Deenadayalan, Srikanth ^e   Jacobsen, Jacob Bonde ^e   Serusclat, Pierre ^f   Violante, Rafael ^g   Watada, Hirotaka ^h   Davies, Melanie ⁱ  

^a Dallas Diabetes and Endocrine Center at Medical City   (United States)

^b Family Health Center   (United States)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e NOVO NORDISK A S   (Denmark)

^f Clinique Les Portes du Sud   (France)

^g INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^h JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; METFORMIN; SEMAGLUTIDE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCREENING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; AGONISTS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DOSE RESPONSE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS;

EID: 85063281339     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2019.2942     Document Type: Article

References (32)

1. Davies MJ, D'Alessio DA, Fradkin J, Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41 (12): 2669-2701. doi: 10.2337/dci18-0033 30291106
2. 1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013; 36 (8): 2271-2279. doi: 10.2337/dc12-2258 23418368
3. American Diabetes Association. Standards of Medical Care in Diabetes-2018, 8: pharmacologic approaches to glycemic treatment. Diabetes Care. 2018; 41 (suppl 1): S73-S85. doi: 10.2337/dc18-S008 29222379
4. Tran S, Retnakaran R, Zinman B, Kramer CK. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2018; 20 (suppl 1): 68-76. doi: 10.1111/dom.13137 29364587
5. Scirica BM, Bhatt DL, Braunwald E,; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369 (14): 1317-1326. doi: 10.1056/NEJMoa1307684 23992601
6. Rosenstock J, Perkovic V, Johansen OE, Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 321 (1): 69-79. doi: 10.1001/jama.2018.18269 30418475
7. Marso SP, Bain SC, Consoli A,; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375 (19): 1834-1844. doi: 10.1056/NEJMoa1607141 27633186
8. Marso SP, Daniels GH, Brown-Frandsen K,; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375 (4): 311-322. doi: 10.1056/NEJMoa1603827 27295427
9. Hernandez AF, Green JB, Janmohamed S,; Harmony Outcomes Committees and Investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392 (10157): 1519-1529. doi: 10.1016/S0140-6736(18)32261-X 30291013
10. Scott LJ. Sitagliptin: a review in type 2 diabetes. Drugs. 2017; 77 (2): 209-224. doi: 10.1007/s40265-016-0686-9 28078647
11. Philippart M, Schmidt J, Bittner B. Oral delivery of therapeutic proteins and peptides: an overview of current technologies and recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens. Drug Res (Stuttg). 2016; 66 (3): 113-120. 26536331
12. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017; 318 (15): 1460-1470. doi: 10.1001/jama.2017.14752 29049653
13. Aroda VR, Rosenstock J, Terauchi Y, Effect and safety of oral semaglutide monotherapy in type 2 diabetes-PIONEER 1 trial. Diabetes. 2018; 67 (suppl 1): 2. doi: 10.2337/db18-2-LB
14. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310 (20): 2191-2194. doi: 10.1001/jama.2013.281053 24141714
15. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6 (R1). June 10, 1996. https://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf. Accessed December 2018.
16. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials: E9. February 5, 1998. https://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E9/Step4/E9-Guideline.pdf. Accessed March 13, 2019.
17. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Estimands and Sensitivity Analysis in Clinical Trials: E9 (R1). June 16, 2017. https://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E9/E9-R1EWG-Step2-Guideline-2017-0616.pdf. Accessed March 13, 2019.
18. Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J. 2011; 53 (6): 894-913. doi: 10.1002/bimj.201000239 21837623
19. Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York, NY: John Wiley & Sons; 1987.
20. Koch GG. Comments on "current issues in non-inferiority trials" by Thomas R. Fleming. Stat Med. 2008; 27 (3): 333-342. doi: 10.1002/sim.2923 17530625
21. Bergenstal RM, Wysham C, Macconell L,; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010; 376 (9739): 431-439. doi: 10.1016/S0140-6736(10)60590-9 20580422
22. Pratley R, Nauck M, Bailey T,; 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011; 65 (4): 397-407. doi: 10.1111/j.1742-1241.2011.02656.x 21355967
23. Ahrén B, Masmiquel L, Kumar H, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017; 5 (5): 341-354. doi: 10.1016/S2213-8587(17)30092-X 28385659
24. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014; 37 (8): 2149-2158. doi: 10.2337/dc13-2761 24742660
25. Stratton IM, Adler AI, Neil HA, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321 (7258): 405-412. doi: 10.1136/bmj.321.7258.405 10938048
26. Stewart KD, Johnston JA, Matza LS, Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016; 10: 1385-1399. doi: 10.2147/PPA.S101821 27528802
27. Rock CL, Flatt SW, Pakiz B, Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014; 37 (6): 1573-1580. doi: 10.2337/dc13-2900 24760261
28. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017; 19 (4): 524-536. doi: 10.1111/dom.12849 27981757
29. Sorli C, Harashima SI, Tsoukas GM, Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5 (4): 251-260. doi: 10.1016/S2213-8587(17)30013-X 28110911
30. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015; 38 (12): 2241-2249. doi: 10.2337/dc14-1625 26089386
31. Ahmann AJ, Capehorn M, Charpentier G, Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018; 41 (2): 258-266. doi: 10.2337/dc17-0417 29246950
32. Buckley ST, Bækdal TA, Vegge A, Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018; 10 (467): eaar7047. doi: 10.1126/scitranslmed.aar7047 30429357